Business, energy, technology, markets and global industry news from Business News Today

pimicotinib

PharmaDeviceNews pimicotinib
Pharma & Biotech

Pimjetmi shrank tumours in 56% of TGCT patients. Can Merck KGaA break through an increasingly crowded rare-tumour market?

FDA approves Pimjetmi after a 56% response rate in Phase 3 TGCT testing, giving Merck KGaA a new once-daily rare-tumour treatment.

Read More
Representative image of a knee joint affected by tenosynovial giant cell tumor (TGCT), the rare condition targeted by pimicotinib, now under FDA review for potential approval as a first-in-class oral CSF-1R inhibitor.
Pharma & Biotech

FDA accepts pimicotinib NDA for TGCT: What this signals for rare tumor drug development and the CSF-1R inhibitor class

Find out how Abbisko’s TGCT drug pimicotinib just crossed a major milestone with the FDA—and what this means for patients and the CSF-1R class.

Read More